KPTIQ

Karyopharm Therapeutics (KPTI.US) soared more than 167% in after-hours trading to $0.0465.

Volume was 25.37 times its average and the intraday swing reached 32.25%.

The Nasdaq Composite is down 1.21% over the past five sessions and up 7.85% year to date.

The company plans to present multiple clinical datasets for selinexor at the American Society of Hematology Annual Meeting from Dec. 12 to 13, 2026. Data from the Phase III SENTRY trial showed that selinexor combined with ruxolitinib continued to demonstrate clinical benefit at week 48 in patients with myelofibrosis.

Separately, Karyopharm has secured unanimous creditor support for its pre-packaged Chapter 11 restructuring plan, with a voting deadline of Nov. 30, 2026.

Based on public media reports. AI-generated; not investment advice.